Krebs Biochemicals and Industries growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−45.2%−14.1%−3.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+63.7%−72.3%+44.7%
+45.3%−40.2%+30.7%
+37.1%−36.6%+20.1%
+37.1%−36.4%+18.9%
−3.4%−5.1%+1.8%
−11.3%−22.7%−19.9%
+75.7%−442.5%+108.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

KREBSBIO₹57.93

Krebs Biochemicals and Industries Limited

· Pharma & Health
₹ CrorePeersALPABALPHARMAVINEETLABNATCAPSUQBIOFILCHEMNECLIFEMANGALAMAAREYDRUGSMcap ₹125 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—-3.3-14.1-45.2—
EBITDA Growth—+44.7-72.3+63.7—
EBIT Growth—+30.7-40.2+45.3—
Net Income Growth—+20.1-36.6+37.1—
EPS Growth—+18.9-36.4+37.1—
Total Assets Growth—+1.8-5.1-3.4—
Total Equity Growth—-19.9-22.7-11.3—
Cash from Operations Growth—+108.7-442.5+75.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.